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OESOPHAGUS
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Background: Photochemical and thermal methods are used for ablating Barrett’s oesophagus (BO). The
aim of this study was to compare 5-aminolevulinic acid induced photodynamic therapy (ALA-PDT) with
argon plasma coagulation (APC) with respect to complete reversal of BO.
Methods: Patients with BO (32 no dysplasia and eight low grade dysplasia) were randomised to one of
three treatments: (a) ALA-PDT as a single dose of 100 J/cm2 at four hours (PDT100; n = 13); (b) ALA-PDT
as a fractionated dose of 20 and 100 J/cm2 at one and four hours, respectively (PDT20+100; n = 13); or
(c) APC at a power setting of 65 W in two sessions (APC; n = 14). If complete elimination of BO was not
achieved by the designated treatment, the remaining BO was treated by a maximum of two sessions of
APC.
Results: Mean endoscopic reduction of BO at six weeks was 51% (range 20–100%) in the PDT100 group,
86% (range 0–100%) in the PDT20+100 group, and 93% (range 40–100%) in the APC group (PDT100 v
PDT20+100, p,0.005; PDT100 v APC, p,0.005; and PDT20+100 v APC, NS) with histologically
complete ablation in 1/13 (8%) patients in the PDT100 group, 4/12 (33%) in the PDT20+100 group, and
5/14 (36%) in the APC group (NS). Remaining BO was additionally treated with APC in 23/40 (58%)
patients. Histological examination at 12 months revealed complete ablation in 9/11 (82%) patients in the
PDT100 group, in 9/10 (90%) patients in the PDT20+100 group, and in 8/12 (67%) patients in the APC
group (NS). At 12 months, no dysplasia was detected. Side effects (that is, pain (p,0.01), and nausea
and vomiting (p,0.05)) and elevated liver transaminases (p,0.01) were more common after PDT than
APC therapy. One patient died three days after treatment with PDT, presumably from cardiac arrhythmia.
Conclusion: APC alone or ALA-PDT in combination with APC can lead to complete reversal of Barrett’s
epithelium in at least two thirds of patients when administered in multiple treatment sessions. As the goal of
treatment should be complete reversal of Barrett’s epithelium, we do not recommend these techniques for
the prophylactic ablation of BO.
B
arrett’s oesophagus (BO) is a premalignant condition in
which the normal squamous epithelium of the distal
oesophagus is replaced by an incomplete form of
intestinal metaplasia, named specialised intestinal metapla-
sia.1 Patients with BO have an age and sex related risk of
0.5% per year of developing adenocarcinoma of the oesopha-
gus.2
Current management of BO includes endoscopic surveil-
lance at intervals determined by the presence of intestinal
metaplasia and the grade of dysplasia within this epithe-
lium.3 The rationale for this approach is that surveillance
detects high grade dysplasia (HGD) and oesophageal
adenocarcinomas at an earlier stage, resulting in a more
favourable outcome compared with carcinomas presenting
with dysphagia.4
A new approach includes the use of endoscopic ablative
techniques in combination with antireflux therapy. These
techniques can be used therapeutically to remove areas of
HGD or early cancer and prophylactically to eliminate the
specialised intestinal metaplasia and replace it by squamous
epithelium. The currently available ablative modalities are
based on photochemical (photodynamic therapy), thermal
(argon plasma coagulation, laser, and multipolar electro-
coagulation and heater probe), and mechanical (endoscopic
mucosal resection) principles.5
Photodynamic therapy (PDT) involves light induced
activation of an administered photosensitiser which leads
to local injury by the production of singlet oxygen. The most
commonly used photosensitiser is porfimer sodium
(Photofrin).6 A novel approach to PDT is endogenous
photosensitisation with 5-aminolevulinic acid (ALA). ALA
by itself has no photosensitising properties but is metabolised
to its photosensitising product protoporphyrin IX.7
Argon plasma coagulation (APC) is a non-contact electro-
coagulation procedure in which high frequency energy is
transmitted to tissue by an ionised gas (argon gas). It induces
coagulation of a tissue thickness of up to 2–3 mm, resulting
in injury of the superficial layers of tissues.8
Currently, all published studies on ablative therapy of BO
have dealt with a single treatment modality. In addition, to
our knowledge, there are no studies which have compared
different techniques of endoscopic reversal of BO. We
performed a randomised study comparing the efficacy of
single or fractionated dose ALA-PDT with APC for the
prophylactic reversal of BO in 40 patients with BO without
dysplasia or with low grade dysplasia (LGD). If complete
elimination of BO was not achieved by the designated
treatment, the remaining BO was ablated by additional APC.
Abbreviations: ALA, 5-aminolevulinic acid; APC, argon plasma
coagulation; BO, Barrett’s oesophagus; HGD, high grade dysplasia;
LGD, low grade dysplasia; PDT, photodynamic therapy; PPIs, proton
pump inhibitors
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PATIENTS AND METHODS
Patients
From January 2001 to July 2002, 40 patients with a BO
length of 2–5 cm were enrolled into the study. Participation
was restricted to patients with specialised intestinal meta-
plasia (Barrett’s metaplasia) and no more than LGD on
histological examination. Written informed consent was
obtained from all patients who were at least 18 years of
age. The study was approved by the Institutional Review
Board of the Erasmus MC Rotterdam, the Netherlands. All
patients were taking proton pump inhibitors (PPIs) for at
least six months before treatment. Exclusion criteria were:
intolerance to (repeated) endoscopy, pregnancy, acute
porphyria, and intercurrent diseases precluding survival
during the study period.
Treatment protocol
All patients underwent baseline endoscopy within two
months prior to treatment. The distribution of BO was
recorded and the total length of BO was measured.
Endoscopic photographs were taken at various levels and
from different angles in the oesophagus and stored as JPEG
files. Four quadrant biopsies were taken at 2 cm intervals
with a standard biopsy forceps. Biopsies were stained with
haematoxylin-eosin, and in some cases with alcian blue at
pH 2.5. All biopsies were reviewed by a single experienced
gastrointestinal pathologist (HvD). Randomisation was per-
formed by the trial centre of the Department of Internal
Oncology, Erasmus MC Rotterdam. Patients were stratified
for the presence of no dysplasia or LGD in baseline biopsies.
For ALA-PDT, 60 mg/kg ALA (Sigma-Aldrich Chemie BV,
Zevenaar, the Netherlands) was dissolved in 20 ml of orange
juice. All patients were kept in a darkened room for 36 hours
after ingestion. Blood cell counts and liver enzymes levels
were determined at baseline and the day after treatment. A
KTP/532 dye laser module (Laser scope, San Jose, California,
USA) delivered light with a wavelength of 630 nm. PDT
illumination schemes were: (a) a single laser illumination
with a fluence (light dose) of 100 J/cm2 at four hours after
ALA administration (PDT100 group) or (b) a fractionated
laser illumination with a fluence of 20 J/cm2 and 100 J/cm2
at one and four hours, respectively, after ALA administration
(PDT20+100 group). Light delivery was performed using an
inflatable balloon with an inflated diameter of 2.5 cm
(Wizzard X-cell; Wilson-Cook Medical, Inc., Winston-
Salem, North Carolina, USA). The total output power of the
cylindrical diffuser (400 mm fibre core diameter)
(CeramOptec GmbH, Bonn, Germany) was measured in an
integrating sphere (Grasbery Optronics S370; TeLintelo
Systems, the Netherlands) and was set to a value yielding a
calculated fluence rate of 100 mW/cm2.9 The cylindrical
diffuser was aligned in the balloon prior to the procedure.
The length of the window of the balloon and the cylindrical
diffuser were either 3 or 5 cm, depending on the estimated
length of BO. The deflated balloon was positioned over a
guidewire and its position was checked endoscopically. The
output power of the cylindrical diffuser was checked prior to
and post ALA-PDT.
For APC, an Argon Beamer 2 device, APC 300 (Erbe
Medizintechnik, Tu¨bingen, Germany) was used with a gas
flow rate of 2 l/min at a power setting of 65 W. We aimed to
ablate two thirds of the oesophageal circumference of BO
during the first session while in the following session the
remainder of the BO was ablated. Ablation was initiated at
the gastro-oesophageal junction and than proceeded long-
itudinally towards the proximal squamocolumnar junction.
APC comprised a maximum of two treatment sessions per
patient at four week intervals.
Follow up protocol
Patients were treated with a daily dose of at least 40 mg
omeprazole (AstraZeneca, Zoetermeer, the Netherlands).
Both patients and their general practitioners were instructed
that this dose of PPI needed to be continued during the study.
Patient symptoms during and after ablative therapy were
recorded. In addition, patients were contacted by telephone
on day 5 after treatment to assess side effects.
Follow up endoscopies were performed at six weeks and at
6, 12, 18, and 24 months after ablative treatment. During
Table 1 Demographic details of patients treated with single dose ALA-PDT (PDT100),
fractionated dose ALA-PDT (PDT20+100), or APC
PDT100 (n = 13) PDT20+100 (n = 13) APC (n = 14)
Age (y) (median (range)) 57 (52–72) 61 (57–69) 60 (41–69)
Sex (M/F) 10/3 10/3 11/3
BO length (cm) (median (range)) 3 (2–5) 3 (3–4) 3 (3–4)
Histology of BO
No dysplasia 10 11 1
LGD 3 2 3
Follow up in months (median (range)) 12 (9–18) 12 (6–24) 12 (9–21)
Mean dose of omeprazole (mg) (median (
range))
46 (40–80) 45 (40–80) 51 (40–80)
ALA, 5-aminolevulinic acid; APC, argon plasma coagulation; BO, Barrett’s oesophagus; LGD, low grade
dysplasia; PDT, photodynamic therapy.
No significant differences between the groups.
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Figure 1 Endoscopic reduction of Barrett’s oesophagus at six weeks
after treatment, in patients given single dose 5-aminolevulinic acid
(ALA)-photodynamic therapy (PDT) (PDT100; n = 13), fractionated dose
ALA-PDT (PDT20+100; n = 12), and argon plasma coagulation (APC)
(n = 14). (PDT100 group v PDT20+100 group, p,0.005; PDT100 group
v APC group, p,0.005; PDT20+100 group v APC group, NS.)
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follow up endoscopies, photographs were taken and stored as
JPEG files. In addition, biopsies were taken from all four
quadrants at 2 cm intervals throughout the BO segment.
Endoscopic pictures were assessed by two investigators (PDS,
MH) who were blinded to the treatment that the patient had
received. On histological examination, samples were scored
for the presence or absence of specialised intestinal metapla-
sia and, if present, whether this was found next to or
underneath (regenerated) squamous epithelium. In addition,
the highest grade of dysplasia was recorded.
If macroscopic BO was observed at the first follow up
endoscopy at six weeks after treatment, this BO was ablated
by additional APC with a maximum of two sessions at four
week intervals.
Results were expressed as: (1) endoscopic reduction of the
BO surface and (2) microscopic presence or absence of
Barrett’s metaplasia at six weeks and at 6, 12, 18, and
24 months after the initial treatment.
Statistical analysis
Endoscopic reduction of the BO surface was compared
between the PDT100 group, PDT20/100 group, and APC
group using Mann-Whitney U tests for all three possible
comparisons. Adjustment for multiple comparisons was not
performed as all three comparisons were considered to be of
interest. Patient demographics, histological results, and
symptoms after ablative treatment were compared using
the x2 test. A difference was considered significant if p,0.05.
RESULTS
Forty (31 males/nine females) patients with a mean BO
length of 3 cm (range 2–5) and no dysplasia (n = 32) or with
LGD (n = 8) on histological examination were included.
Median age of all patients was 59 years (range 41–72). The
mean dose of omeprazole after treatment was 47.5 mg (range
40–80). The three patients groups were demographically
similar (table 1).
All patients completed the designated ablative therapy. Of
the 26 patients treated with ALA-PDT, 24 (96%) showed
endoscopic reduction of BO at six weeks after treatment
(fig 1). One patient treated with a fractionated dose of PDT
showed no response and another patient treated with a
fractionated dose of PDT died shortly after treatment (see
below). Mean endoscopic BO surface reduction was 51%
(range 20–100%) in the PDT100 group and 86% (range
0–100%) in the PDT20+100 group. No endoscopic evidence of
remaining BO was seen in one (8%) patient in the PDT100
group and in five (42%) patients in the PDT20+100J group.
All 14 patients treated with APC showed endoscopic
reduction of BO at six weeks after treatment. Mean
endoscopic regression was 93% (range 40–100%). No endo-
scopic evidence of remaining BO was seen in seven (50%)
patients in the APC group (PDT100 group v PDT20+100
group, p,0.005; PDT100 group v APC group, p,0.005;
PDT20+100 group v APC group, NS).
Histological evaluation at six weeks after treatment
revealed complete reversal of BO in one (8%) patient in the
PDT100 group, in four (33%) patients in the PDT20+100
group, and in five (36%) patients in the APC group (NS). The
presence of BO after treatment was predominantly found as
BO next to (regenerated) squamous epithelium in both PDT
groups. In the APC group, BO was found as BO underneath
squamous epithelium (sub-squamous BO) in 7/9 patients
(table 2).
All patients with macroscopic BO at the follow up
endoscopy at six weeks received additional APC treatment
in one (20 patients) or two (three patients) sessions (fig 2).
Follow up endoscopy at six months showed macroscopic BO
in one (7%) patient in the APC group (table 3) whereas
histological evidence of BO was found in one patient in the
PDT100 group and in three patients in the APC group.
Endoscopic presence of BO at 12 months was observed in one
patient in the PDT100 group and in two (17%) patients in the
APC group. Histological examination at 12 months revealed
BO in two patients in the PDT100 group, in one patient in the
PDT20+100 group, and in four patients in the APC group.
Endoscopic BO at 18 months was observed in two patients in
the PDT100 group and in two patients in the APC group
whereas histological evidence of BO was found in two
patients in the PDT100 group, in one patient in the
PDT20+100 group, and in three patients in the APC group.
During follow up, no dysplasia was observed in any of the
biopsies with remaining BO.
Side effects are shown in table 4. Pain during treatment,
and nausea and vomiting were more common in patients
treated with ALA-PDT compared with APC. One patient
treated with APC developed a stricture which was effec-
tively treated by a single session of dilation. Another patient
treated with a fractionated dose of ALA-PDT died suddenly
Table 2 Microscopic evaluation at six weeks after
treatment in patients treated with single dose ALA-PDT
(PDT100; n = 13), fractionated dose ALA-PDT
(PDT20+100; n = 12), or APC (n = 14)
No BO Residual BO Sub-squamous BO
PDT100 1 12 0
PDT20+100 4 7 1
APC 5 4* 5
ALA, 5-aminolevulinic acid; APC, argon plasma coagulation; BO,
Barrett’s oesophagus; PDT, photodynamic therapy.
*Two of these patients also had sub-squamous BO.
No significant differences between the groups.
Figure 2 Endoscopic views of a patient with Barrett’s oesophagus (BO): (A) before treatment, (B) 80% reversal of BO at six weeks after treatment with
a fractionated dose of 5-aminolevulinic acid-photodynamic therapy, and (C) complete reversal of BO at six months after additional treatment with
argon plasma coagulation.
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three days after treatment. This patient had left hospital one
hour earlier and had not reported clinical symptoms at the
moment of departure. At autopsy, the oesophageal wall
showed microscopic signs of transmural necrosis without
perforation. Although an atherosclerotic change of the
arterial blood vessels was observed, no evidence of an
ischaemic cardiovascular event was found. The autopsy
revealed no clear explanation for the sudden death in this
patient. Twenty patients treated with ALA-PDT had mild
elevation of transaminase levels the day after treatment
(aspartate aminotransferase: mean 62 U/l (range 39–89)
(reference 5–30 U/l); alanine transferase: mean 72 U/l (range
51–116) (reference 10–40 U/l)). At six weeks, liver enzyme
levels in all patients had normalised.
DISCUSSION
This is the first study in which a photochemical method for
removing BO (that is, ALA-PDT) was compared with a
presently available thermal modality (that is, APC) for
prophylactic reversal of Barrett’s intestinal metaplasia to
squamous epithelium.
Single treatment with ALA-PDT and APC initially reduced
the total surface of BO by 96% and 100%, respectively (fig 1).
However, complete elimination of BO was seen in only five of
25 (20%) patients treated with ALA-PDT alone and in five of
14 (36%) patients treated with two sessions of APC at
6 weeks after treatment (table 2). After subsequent treat-
ment with APC in patients with persistent BO at the first
follow up endoscopy at six weeks, complete microscopic
reversal was obtained in 18 of 21 (86%) patients in both ALA-
PDT groups and in eight of 12 (67%) patients in the APC
group at 12 months after the initial treatment (table 3). In
patients with residual BO, no evidence of dysplasia was
found.
How do our results compare with other studies? Two larger
studies on the use of ALA-PDT for BO have been published.
One therapeutic study by Gossner and colleagues10 reported
eradication of HGD in BO in all 10 patients and elimination of
intramucosal cancer in 17 of 22 patients, mostly after two
separate ALA-PDT treatments. Squamous re-epithelialisation
was observed in only two thirds of patients and was
incomplete in all of them. In another study by Ackroyd and
colleagues,11 18 patients with LGD in BO were treated by one
session of ALA-PDT. The median decrease in the surface of
BO was 30%, and none of the control biopsies from
remaining Barrett’s epithelium showed dysplasia.
We applied two different PDT illumination schemes: (a) a
single illumination scheme with an energy dose of 100 J/cm2
at four hours and (b) a fractionated illumination scheme
with an energy dose of 20 J/cm2 and 100 J/cm2 at one and
four hours, respectively, after ALA ingestion. The latter
scheme was chosen because our previous experimental work
had shown that a fractionated ALA-PDT scheme increased
cell death in human EBV transformed cell lines. We
demonstrated that an early course of ALA-PDT inhibited
the haeme biosynthetic enzyme ferrochelatase while the
activity of another rate limiting enzyme, porphobilinogen
deaminase, remained intact. This resulted in increased
accumulation of the photosensitiser protoporphyrin IX and
increased efficacy of a second course of ALA-PDT.12 There is
however no agreement in the literature on whether a
fractionated illumination scheme enhances the therapeutic
effect of PDT.13 14 In agreement with our experimental results,
we found that the fractionated dose of ALA-PDT caused more
pronounced regression of BO at six weeks than the single
dose, both macroscopically (fig 1) and microscopically
(table 2), although the latter did not reach statistical
significance.
The use of APC for reversing BO has been reported in
several studies.15–22 In these studies, complete reversal of BO
ranged from 42% to 98% after 1–6 treatments with APC. In
our study, 67% of patients had a complete histological
response one year after 2–4 treatment sessions with APC
(table 3). This somewhat disappointing result can, at least in
part, be explained by our strict definition of persistent BO,
according to which any biopsy showing specialised columnar
epithelium was considered to be persistent BO. Islands of BO
underlying newly formed squamous epithelium were found
in 7/9 patients with an incomplete response after the initial
treatment with APC. Sub-squamous islands of BO were more
often found after APC (50%) than after ALA-PDT (4%)
(table 2) which is in accordance with the findings of
others.10 21 Sub-squamous BO may regress or remain clinically
unimportant if protected by the newly formed squamous
epithelium from repeated attacks by gastric and duodenal
fluid. However, there are reasons to believe that these islands
Table 3 Barrett’s oesophagus during follow up in patients treated with single dose ALA-
PDT (PDT100), fractionated dose ALA-PDT (PDT20+100), or APC, in some patients
followed by treatment with APC for residual Barrett’s oesophagus
Follow up
(months)
PDT100 group PDT20+100 group APC group
Endoscopic BO
(%)
Histological BO
(%)
Endoscopic BO
(%)
Histological BO
(%)
Endoscopic BO
(%)
Histological BO
(%)
6 0/13 1/13 (8) 0/12 0/12 1/14 (7) 3/14 (21)
12 1/11 (9) 2/11 (18) 0/10 1/10 (10) 2/12 (17) 4/12 (33)
18 2/8 (25) 2/8 (25) 0/8 1/8 (12) 2/9 (22) 3/9 (33)
24 NA NA 0/2 0/2 NA NA
*NA, not applicable.
ALA, 5-aminolevulinic acid; APC, argon plasma coagulation; BO, Barrett’s oesophagus; PDT, photodynamic
therapy.
No significant differences between the groups.
Table 4 Side effects and complications in patients
treated with ALA-PDT (single dose and fractionated dose
combined) or APC
PDT (n = 26) APC (n = 14) p Value
Pain during treatment 23 5 ,0.01
Odynophagia 24 12 NS
Fever 8 2 NS
Nausea and vomiting 7 0 ,0.05
Sudden death 1* 0 NS
Stricture formation 0 1 NS
Elevated liver enzyme tests 20 0 ,0.01
ALA, 5-aminolevulinic acid; APC, argon plasma coagulation; PDT,
photodynamic therapy.
*Patient died, presumably from cardiac arrhythmia.
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retain their malignant potential. At least two cases of
adenocarcinoma arising under the newly formed squamous
epithelium have been reported after APC.23 24
It has been suggested that the results of APC can be
improved by using a power setting of 65 W or more. Higher
power APC settings may result in deeper tissue destruction
and therefore more complete ablation of BO.17 18 In addition,
recurrence of BO after APC was found to be related to the
presence of a long segment of BO (.3 cm) and to persistent
acid reflux, as measured by pH monitoring and/or reduction
of PPI dose.21 22 In our study, we performed APC at a power
setting of 65 W, the median length of BO was 3 cm, and the
mean daily dose of omeprazole was 45 mg in the APC
treatment group. As oesophageal pH monitoring was not
performed in our study, we cannot exclude the fact that
incomplete ablation of BO may also be explained by higher
exposure to pH levels ,4 in these patients.
Until a few years ago, the main goal of ablative therapy was
histological downgrading of dysplasia. Recent studies have
however demonstrated that genetic abnormalities can persist
in BO after ablative therapy.25 26 In addition, van
Hillegersberg and colleagues27 recently described two patients
who developed adenocarcinoma after incomplete endoscopic
ablation of Barrett’s epithelium. Therefore, the goal of
treatment should be complete elimination of all Barrett’s
metaplastic tissue. Whenever macroscopic BO was observed
at the first follow up endoscopy at six weeks, we treated this
with additional APC, resulting in a further increase in the
number of patients macroscopically and microscopically free
of BO at 12 months of follow up. However, of the more than
60% of patients followed up for 18 months, 12–33% were still
found to have BO next to or underneath the regenerated
squamous epithelium (table 3). Therefore, the injury pro-
duced by ALA-PDT, APC, or a combination of both, was not
sufficient to completely reverse BO in all patients. As BO is
thought to originate from cells in the deeper layers of the
oesophageal wall,28 it may be well that even after complete
reversal of Barrett’s epithelium, and in the presence of
persistent acid reflux, recurrent growth of BO is more
successful than squamous regeneration.
One of the reasons why the photosensitiser ALA has
become more popular than Photofrin in Europe is its
presumed lower incidence of side effects. We saw no skin
photosensitivity after ALA-PDT. In contrast, owing to its long
half life, patients are advised to avoid sunlight (UV) for a
period of 4–6 weeks after being treated with Photofrin. No
strictures were observed in our patients treated with ALA-
PDT while strictures have been reported in 34% of patients
given Photofrin.6 Severe chest pain during treatment was an
important side effect of ALA-PDT, necessitating the use of
high doses of analgesics (table 4). Another (transient) side
effect of ALA-PDT was a two- to threefold increase in
transaminase levels, reflecting liver parenchyma damage.
Independent of the presence of light, a local autocatalytic
interaction between ALA, iron, and oxygen has been
demonstrated in the liver which could be responsible for
the parenchyma specific increase in liver enzymes.29 Finally,
an unexpected finding was a sudden death in a patient who
was treated with a fractionated dose of ALA-PDT three days
before his death. He had no clinical symptoms when leaving
hospital, and collapsed one hour after having been dis-
charged. Autopsy showed microscopic signs of transmural
necrosis of the oesophageal wall at the site where the
treatment had been performed but no evidence of perforation
or mediastinal inflammation. In an earlier study, we also
observed necrosis of the layers of the oesophageal wall in rats
treated with PDT. None of these rats developed perforation of
the oesophagus.30 A possible explanation for the unexpected
death in this patient may have been cardiac arrhythmia.
Atrial fibrillation has been reported during and following
oesophageal PDT.31 32
In conclusion, APC alone or ALA-PDT in combination with
APC can lead to complete reversal of Barrett’s epithelium in
at least two thirds of patients when administered in multiple
treatment sessions. Single modality treatment (ALA-PDT
alone or APC in two sessions) resulted in persistence of BO in
the majority of patients, even when the immediate post-
treatment macroscopic appearance suggested adequate treat-
ment. We were unable to show a significant difference in
efficacy between the treatments. Treatment with ALA-PDT
was accompanied by more side effects than APC. As the goal
of treatment should be complete reversal of Barrett’s
epithelium to squamous epithelium, we do not recommend
these techniques for the prophylactic ablation of BO.
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